Every day, more lives are transformed all over the world – one healthy habit at a time. Read the latest about how Medifast and the OPTAVIA® movement is impacting people’s lives.
"Maintain by Medifast™" is a science-based program, which has been in clinical testing for more than two years at Johns Hopkins Bloomberg School of Health. The study's preliminary results, which summarized the first thirty- four weeks of the study, showed that consumers were twice as compliant and lost twice as much weight as compared with the group on the American Diabetic Association-recommended food plan. Furthermore, there were significant health improvements with the patients on the Medifast program.
The "Maintain by Medifast™" products will now be rolled out to selective clinics and pharmacies in addition to Medifast's direct primary care physician, patients, and television customers. The company's Hi-Energy Clinics will also launch the program in its more than one hundred clinics across the United States under their own label. Finally, the company's Take Shape for Life division and its certified health advisors, under Dr. Wayne S. Andersen, will also offer the program.
"We are excited to launch our science-based diabetic program and appear on such a high-profile network at such an opportune time," said Brad MacDonald, Medifast's chairman and chief executive officer. "New Year's Day is an important time for the weight loss industry, as it marks the beginning of making resolutions for the new year, one of which is to change our habits and live a healthier lifestyle. This launch generated significant consumer interest and sales, and we are confident that this will enable us to begin 2005 strongly. We will be able to build on the success of our 'Maintain by Medifast™' line throughout the year."
Unlike some other leading weight-loss programs, Medifast has conducted numerous clinical studies to support its protocols and claims. In addition to the current diabetic study, since the 1980s, Medifast has conducted two previous studies at Johns Hopkins, and a National Institute of Health- sponsored study at the University of Vermont. In addition, the company is sponsoring a groundbreaking Adolescent Obesity Study with the Johns Hopkins Bloomberg School of Health.
Mr. MacDonald says, "The purpose of these clinical studies is to provide the consumer with the best available products and technologies to solve their weight management problems and relieve the symptoms of the major diseases related to obesity."
This release contains forward-looking statements, which may involve known and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.
SOURCE: Medifast, Inc.
CONTACT: Jeremy Hunt, Investor Relations Specialist, Medifast, Inc.,
+1-410-504-8196; or Ken Sgro, CEOcast, Inc. for Medifast, +1-212-732-4300
Web site: http://www.medifastdiet.com/